Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $1,066.00 and $680.00 and has a mean target at $920.00. Given that the stocks previous close was at $798.83 this would indicate that there is a potential upside of 15.2%. Also worth taking note is the 50 day moving average now sits at $815.67 while the 200 day moving average is $782.80. The market cap for the company is 87.13B. The stock price for the company is currently $799.73 USD
The potential market cap would be $100,344,158,823 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 22.83, revenue per share of $122.63 and a 9.21% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
